Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.

Core Viewpoint - Zura Bio Limited, a clinical-stage biotechnology company, announced the appointment of two new members to its Board of Directors, indicating a strategic move to enhance its leadership team as it develops treatments for autoimmune and inflammatory diseases [1] Group 1: Company Developments - Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., have been appointed to the Board of Directors, effective February 21, 2026 [1] - This transition in leadership may reflect the company's commitment to advancing its clinical programs and improving patient outcomes in serious diseases [1] Group 2: Industry Context - The appointments come at a time when the biotechnology sector is increasingly focused on innovative treatments for autoimmune and inflammatory conditions, highlighting the competitive landscape in which Zura operates [1]